^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Small Cell Lung Cancer
    Drug:nibrozetone (RRx-001) (CD47 inhibitor, MYC inhibitor, NLRP3 inhibitor, SIRPA antagonist, NRF2 activator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Transl Lung Cancer Res
    Title:

    In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit

    Published date:
    10/12/2020
    Excerpt:
    The logistic model analyzing the association between decreased PD-L1 expression on CTCs after RRx-001 and response to platinum-based doublet therapy had an approximate 92.8% accuracy in its prediction of clinical benefit (SD/PR/CR).
    Secondary therapy:
    Chemotherapy
    DOI:
    10.21037/tlcr-20-359
    Trial ID:
    QUADRUPLE THREAT